Ferrone Cristina, Goyal Lipika, Qadan Motaz, Gervais Debra, Sahani Dushyant V, Zhu Andrew X, Hong Theodore S, Blaszkowsky Lawrence S, Tanabe Kenneth K, Vangel Mark, Amorim Barbara J, Wo Jennifer Y, Mahmood Umar, Pandharipande Pari V, Catana Ciprian, Duenas Virginia P, Collazo Yolanda Q, Canamaque Lina G, Domachevsky Liran, Bernstine Hanna H, Groshar David, Shih Tiffany Tsing-Fang, Li Yan, Herrmann Ken, Umutlu Lale, Rosen Bruce R, Catalano Onofrio A
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Department of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1871-1884. doi: 10.1007/s00259-019-04558-3. Epub 2019 Nov 8.
Intrahepatic cholangiocarcinoma (ICC) is associated with a poor prognosis with surgical resection offering the best chance for long-term survival and potential cure. However, in up to 36% of patients who undergo surgery, more extensive disease is found at time of operation requiring cancellation of surgery. PET/MR is a novel hybrid technology that might improve local and whole-body staging in ICC patients, potentially influencing clinical management. This study was aimed to investigate the possible management implications of PET/MR, relative to conventional imaging, in patients affected by untreated intrahepatic cholangiocarcinoma.
Retrospective review of the clinicopathologic features of 37 patients with iCCC, who underwent PET/MR between September 2015 and August 2018, was performed to investigate the management implications that PET/MR had exerted on the affected patients, relative to conventional imaging.
Of the 37 patients enrolled, median age 63.5 years, 20 (54%) were female. The same day PET/CT was performed in 26 patients. All patients were iCCC-treatment-naïve. Conventional imaging obtained as part of routine clinical care demonstrated early-stage resectable disease for 15 patients and advanced stage disease beyond the scope of surgical resection for 22. PET/MR modified the clinical management of 11/37 (29.7%) patients: for 5 patients (13.5%), the operation was cancelled due to identification of additional disease, while 4 "inoperable" patients (10.8%) underwent an operation. An additional 2 patients (5.4%) had a significant change in their operative plan based on PET/MR.
When compared with standard imaging, PET/MR significantly influenced the treatment plan in 29.7% of patients with iCCC.
2018P001334.
肝内胆管癌(ICC)预后较差,手术切除是实现长期生存及潜在治愈的最佳机会。然而,高达36%接受手术的患者在手术时发现疾病范围更广,需要取消手术。PET/MR是一种新型混合技术,可能改善ICC患者的局部及全身分期,从而潜在地影响临床管理。本研究旨在探讨PET/MR相对于传统成像,对未经治疗的肝内胆管癌患者可能产生的管理影响。
回顾性分析2015年9月至2018年8月期间接受PET/MR检查的37例iCCC患者的临床病理特征,以研究PET/MR相对于传统成像对受影响患者的管理影响。
纳入的37例患者中,中位年龄63.5岁,20例(54%)为女性。26例患者在同一天进行了PET/CT检查。所有患者均为未经治疗的iCCC。作为常规临床护理一部分获得的传统成像显示,15例患者为早期可切除疾病,22例为超出手术切除范围的晚期疾病。PET/MR改变了11/37(29.7%)患者的临床管理:5例患者(13.5%)因发现额外疾病而取消手术,而4例“不可手术”患者(10.8%)接受了手术。另外2例患者(5.4%)基于PET/MR其手术计划有显著改变。
与标准成像相比,PET/MR显著影响了29.7%的iCCC患者的治疗计划。
2018P001334。